Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients.
Martín-Sánchez E, Garcés JJ, Maia C, Inogés S, López-Díaz de Cerio A, Carmona-Torre F, Marin-Oto M, Alegre F, Molano E, Fernandez-Alonso M, Perez C, Botta C, Zabaleta A, Alcaide AB, Landecho MF, Rua M, Pérez-Warnisher T, Blanco L, Sarvide S, Vilas-Zornoza A, Alignani D, Moreno C, Pineda I, Sogbe M, Argemi J, Paiva B, Yuste JR. Martín-Sánchez E, et al. Among authors: yuste jr. Front Immunol. 2021 May 3;12:659018. doi: 10.3389/fimmu.2021.659018. eCollection 2021. Front Immunol. 2021. PMID: 34012444 Free PMC article.
Staphylococcus aureus nasal carriage among medical students.
Carmona-Torre F, Torrellas B, Rua M, Yuste JR, Del Pozo JL. Carmona-Torre F, et al. Among authors: yuste jr. Lancet Infect Dis. 2017 May;17(5):477-478. doi: 10.1016/S1473-3099(17)30188-3. Lancet Infect Dis. 2017. PMID: 28447948 No abstract available.
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R. Chaccour C, et al. Among authors: yuste jr. Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z. Trials. 2020. PMID: 32513289 Free PMC article.
Immunologic characterization of COVID-19 patients with hematological cancer.
Maia C, Martín-Sánchez E, Garcés JJ, De Cerio AL, Inogés S, Landecho MF, Gil-Alzugaray B, Perez C, Botta C, Zabaleta A, Alegre F, Rincón C, Blanco L, Sarvide S, Vilas-Zornoza A, Alignani D, Moreno C, Paiva A, Martinho A, Alves R, Colado E, Quirós C, Olid M, Blanco A, Argemi J, Paiva B, Yuste JR. Maia C, et al. Among authors: yuste jr. Haematologica. 2020 Dec 17;106(5):1457-1460. doi: 10.3324/haematol.2020.269878. Haematologica. 2020. PMID: 33327714 Free PMC article.
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F, Giráldez M, Laso E, Gabaldón-Figueira JC, Dobaño C, Moncunill G, Yuste JR, Del Pozo JL, Rabinovich NR, Schöning V, Hammann F, Reina G, Sadaba B, Fernández-Alonso M. Chaccour C, et al. Among authors: yuste jr. EClinicalMedicine. 2021 Feb;32:100720. doi: 10.1016/j.eclinm.2020.100720. Epub 2021 Jan 19. EClinicalMedicine. 2021. PMID: 33495752 Free PMC article.
56 results